MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2019 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
60.5 M |
Market Cap[1] |
$ 76.9 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Amarin Corporation plc
AMRN
|
$ 12.29 | 1.99 % | $ 5.1 B | Nasdaq Global Market |  Irlanda |
 |
Editas Medicine
EDIT
|
$ 2.72 | 4.62 % | $ 241 M | Nasdaq Global Select Market,SPB | USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 31.42 | 0.71 % | $ 1.82 B | Nasdaq Global Select Market,SPB | USA |
 |
Cue Biopharma
CUE
|
$ 19.81 | -5.03 % | $ 1.88 B | Nasdaq Capital Market,SPB | USA |
 |
Equillium
EQ
|
$ 1.39 | -1.42 % | $ 79.7 M | Nasdaq Global Market | USA |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.9 | 4.97 % | $ 108 M | Nasdaq Global Select Market,SPB | USA |
 |
Abeona Therapeutics
ABEO
|
$ 4.22 | -0.82 % | $ 223 M | Nasdaq Capital Market | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 21.49 | 4.47 % | $ 3.62 B | Nasdaq Global Select Market,SPB | USA |
 |
Atossa Therapeutics
ATOS
|
$ 2.12 | -9.01 % | $ 18.3 M | Nasdaq Capital Market | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | Nasdaq Capital Market | USA |
 |
AC Immune SA
ACIU
|
$ 2.25 | 7.66 % | $ 227 M | Nasdaq Global Market |  Schweiz |
 |
Five Prime Therapeutics, Inc.
FPRX
|
- | - | $ 1.77 B | Nasdaq Global Select Market | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 1.72 | 10.65 % | $ 219 M | NYSE | Schweiz |
 |
Harmony Biosciences Holdings
HRMY
|
$ 34.48 | -6.87 % | $ 1.98 B | Nasdaq Global Select Market | USA |
 |
Ardelyx
ARDX
|
$ 3.29 | 8.42 % | $ 793 M | Nasdaq Global Market | USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.69 | -4.49 % | $ 177 M | Nasdaq Global Market | USA |
 |
Alector
ALEC
|
$ 2.29 | 11.61 % | $ 236 M | Nasdaq Global Select Market,SPB | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.36 | 5.04 % | $ 73 M | Nasdaq Global Select Market,SPB | USA |
 |
Amneal Pharmaceuticals
AMRX
|
$ 19.93 | -1.36 % | $ 6.25 B | NYSE | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.03 | 3.74 % | $ 772 M | Nasdaq Global Select Market |  Canada |
 |
Agenus
AGEN
|
$ 6.99 | 4.72 % | $ 208 M | Nasdaq Capital Market | USA |
 |
Immutep Limited
IMMP
|
$ 2.93 | -2.17 % | $ 4.27 B | Nasdaq Global Market |  Australia |
 |
AbCellera Biologics
ABCL
|
$ 12.14 | -0.37 % | $ 3.63 B | Nasdaq Global Select Market | Canada |
 |
Artelo Biosciences
ARTL
|
$ 2.33 | -2.92 % | $ 441 K | Nasdaq Global Select Market | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.37 | 0.74 % | $ 432 K | Nasdaq Capital Market | USA |
 |
Aligos Therapeutics
ALGS
|
$ 5.03 | 5.89 % | $ 49.7 M | Nasdaq Global Select Market | USA |
 |
Aclaris Therapeutics
ACRS
|
$ 3.67 | -2.01 % | $ 450 M | Nasdaq Global Select Market | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 26.7 | 3.49 % | $ 4.05 B | Nasdaq Global Select Market,SPB | USA |
 |
Cellectar Biosciences
CLRB
|
$ 1.24 | -5.34 % | $ 3.23 M | Nasdaq Capital Market | USA |
 |
Larimar Therapeutics
LRMR
|
$ 2.78 | 9.25 % | $ 231 M | Nasdaq Global Market | USA |
 |
Biofrontera AG
BFRA
|
- | -8.24 % | $ 105 M | Nasdaq Capital Market |  Germany |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
- | -6.97 % | $ 657 M | Nasdaq Global Market | USA |
 |
Capricor Therapeutics
CAPR
|
$ 8.81 | 6.92 % | $ 409 M | Nasdaq Capital Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 28.0 | 3.24 % | $ 1.31 B | Nasdaq Global Select Market | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
- | 1.68 % | $ 4.65 B | Nasdaq Global Select Market |  China |
 |
Jazz Pharmaceuticals plc
JAZZ
|
$ 234.59 | 2.11 % | $ 14.3 B | Nasdaq Global Select Market | Irlanda |
 |
Aquestive Therapeutics
AQST
|
$ 3.78 | -2.58 % | $ 404 M | Nasdaq Global Market | USA |
 |
Arvinas
ARVN
|
$ 7.41 | 4.51 % | $ 525 M | Nasdaq Global Select Market,SPB | USA |
 |
Cerus Corporation
CERS
|
$ 2.44 | 4.06 % | $ 465 M | Nasdaq Global Market | USA |
 |
Beam Therapeutics
BEAM
|
$ 27.76 | 5.41 % | $ 2.75 B | Nasdaq Global Select Market | USA |
 |
Fortress Biotech
FBIO
|
$ 1.97 | 1.55 % | $ 55 M | Nasdaq Capital Market | USA |
 |
Inhibrx
INBX
|
$ 86.79 | 7.04 % | $ 4.09 B | Nasdaq Global Select Market | USA |
 |
Entera Bio Ltd.
ENTX
|
$ 3.17 | 3.93 % | $ 146 M | Nasdaq Capital Market |  Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
- | - | $ 459 M | Nasdaq Global Market | USA |
 |
Legend Biotech Corporation
LEGN
|
$ 22.8 | 6.12 % | $ 8.41 B | Nasdaq Global Select Market | USA |
 |
CytomX Therapeutics
CTMX
|
$ 2.35 | 7.57 % | $ 324 M | Nasdaq Global Select Market | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
$ 316.11 | 0.82 % | $ 6.11 B | Nasdaq Global Select Market,SPB | USA |
 |
Longeveron
LGVN
|
$ 1.81 | 1.69 % | $ 31.8 B | Nasdaq Global Select Market | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.57 | 5.74 % | $ 154 M | Nasdaq Capital Market | USA |
 |
Heron Therapeutics
HRTX
|
$ 0.3 | 3.65 % | $ 50 M | Nasdaq Global Select Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.